Pharmassist receives state fund as a consortium partner for the "Transcell" project.


Within the context of the second round of State-Aid Action on Research, Technological Development & Innovation entitled "Research-Create-Innovate", Pharmassist is funded as a consortium partner for a very promising and innovative project. Τhe "Transcell" proposal aims to develop and administer advanced T-cell therapies by using cost-effective and “user-friendly” protocols for the treatment of life-threatening infections and GvHD (graft vs host disease), representing the major complications of post allogeneic hematopoietic stem cell transplantation (allo-HSCT). This endeavor will be accomplished through a productive and complementary partnership among three (3) research organizations and two (2) enterprises.
The involvement of Pharmassist is very crucial, since it will undertake the conduct of the two clinical studies accordingly, coordinating and carrying out the entire spectrum of activities. Furthermore, Pharmassist shall file the patent application as well as map the promotional plans for the products.
Pharmassist’s total budget has reached the amount of €159.000 of an overall project budget of €997.087.

This research has been co‐financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE (project code: T2ΕΔΚ-02437).